Scientist Develops Skin Patch Vaccine Protects Against Influenza

[legendguru]

BOOK INTERNATIONAL FLIGHTS TICKETS LOCAL FLIGHTS HOTELS BOOKINGS WORLDWIDE AND MORE AT CHEAPEST RATE EVER! CLICK HERE TO BOOK YOUR FLIGHT AND RECEIVE YOUR FLIGHT TICKET INSTANTLY

Scientists have developed a skin patch that may soon take the “ouch” out of being vaccinated.

Every year, in the United States, less than half of the adults who should get a flu vaccine actually get the shot. That's a problem because while most people tend to think of influenza as a mild disease, the infection can be deadly, especially in the elderly, young children and people with compromised immune systems.

To help raise that percentage researchers have developed a self-administered skin patch to protect against seasonal influenza as well as a shot. Researchers who developed the vaccine patch said it has a lot of advantages over an injection.

Nadine Rouphael was principal investigator of the patch at Emory University School of Medicine in Georgia where she’s a professor of infectious diseases. “The patch looks more like a Band Aid, like a nicotine patch, and then it has multiple very small needles that contain, in this case, influenza vaccine. Those microneedles completely dissolve into the skin and there will be no sharp waste afterwards,” said Rouphael.

The flu vaccine is currently administered by an injection into the muscle of the upper arm. It is painful and can leave some redness and swelling, which is why an estimated 60 percent of adults do not get immunized against seasonal flu.

In the first human clinical trial of the patch at Emory's Hope Clinic, 100 participants aged 18-49, tested the effectiveness of the vaccine patch.

The trial, reported in the journal The Lancet, took place in June 2015. None of the participants had received a flu vaccine during the previous influenza season. The participants were divided into four groups. In one group the patch was administered by a health care provider, in the second it was self-administered by each participant, a third group received the vaccine via injection and a fourth group got a placebo.